SevenBridge Financial Group LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 1.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,360 shares of the company’s stock after acquiring an additional 681 shares during the quarter. Merck & Co., Inc. makes up about 1.7% of SevenBridge Financial Group LLC’s holdings, making the stock its 15th largest holding. SevenBridge Financial Group LLC’s holdings in Merck & Co., Inc. were worth $3,229,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Titan Capital Management LLC CA acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $25,000. LFA Lugano Financial Advisors SA grew its position in Merck & Co., Inc. by 250.0% in the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares during the period. JJJ Advisors Inc. purchased a new position in Merck & Co., Inc. in the second quarter worth approximately $27,000. Cumberland Partners Ltd purchased a new position in Merck & Co., Inc. in the second quarter worth approximately $40,000. Finally, Fusion Family Wealth LLC grew its position in Merck & Co., Inc. by 268.2% in the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares during the period. 74.97% of the stock is owned by institutional investors and hedge funds.
MRK has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $90.00 to $93.00 and gave the stock an “overweight” rating in a research report on Friday, June 14th. Argus increased their price objective on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Citigroup increased their price objective on Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. They noted that the move was a valuation call. Credit Suisse Group reiterated a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. Finally, ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $93.29.
Shares of MRK traded up $0.49 during midday trading on Wednesday, hitting $83.78. 921,440 shares of the stock were exchanged, compared to its average volume of 10,285,667. Merck & Co., Inc. has a 52-week low of $66.10 and a 52-week high of $87.35. The stock has a fifty day simple moving average of $84.66 and a 200 day simple moving average of $82.22. The firm has a market cap of $216.07 billion, a P/E ratio of 19.30, a P/E/G ratio of 1.73 and a beta of 0.53. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21.
Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The business had revenue of $11.76 billion during the quarter, compared to analyst estimates of $10.94 billion. During the same period last year, the business posted $1.06 earnings per share. The company’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, equities research analysts forecast that Merck & Co., Inc. will post 4.92 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Monday, October 7th. Stockholders of record on Monday, September 16th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $2.20 annualized dividend and a dividend yield of 2.63%. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.
In other news, EVP Richard R. Deluca sold 6,427 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the transaction, the executive vice president now directly owns 103,223 shares in the company, valued at $8,783,245.07. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.27% of the company’s stock.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Further Reading: What is a Special Dividend?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.